Page last updated: 2024-08-23

bromocriptine and selegiline

bromocriptine has been researched along with selegiline in 66 studies

Research

Studies (66)

TimeframeStudies, this research(%)All Research%
pre-199019 (28.79)18.7374
1990's25 (37.88)18.2507
2000's16 (24.24)29.6817
2010's6 (9.09)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Adkison, KK; Humphreys, JE; Mahar Doan, KM; Polli, JW; Serabjit-Singh, CJ; Shampine, LJ; Webster, LO; Wring, SA1
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL1
González-Díaz, H; Orallo, F; Quezada, E; Santana, L; Uriarte, E; Viña, D; Yáñez, M1
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1
Oliveri, V1
Rinne, UK1
Lander, CM; Lees, A; Stern, G1
Yahr, MD1
Lieberman, A1
Levivier, M; Przedborski, S1
Jacobs, MB; Varon, J1
Ogawa, N1
Calne, DB; Calne, S; Douglas, J; Postnikoff, D; Poulin, K; Ross, S; Tsui, JK; Woodward, W1
LeWitt, PA1
Birkmayer, JD; Birkmayer, W1
Aminoff, MJ1
Dubuis, R1
Birkmayer, W1
Calne, DB; Rinne, UK1
Wirz, D1
Hietala, J; Koulu, M; Scheinin, M; Syvälahti, E1
Weiner, M1
Birkmayer, W; Danielczyk, W; Jellinger, K; Koppel, H; Reynolds, GP; Riederer, P; Seemann, D; Ulm, G1
Bihari, K; Csanda, E; Köves, A; Mogyorós, I; Takáts, A; Tárczy, M1
Koulu, M; Lammintausta, R1
Da Prada, M; Haefely, WE; Keller, HH; Kettler, R; Pieri, L1
Agnoli, A; Baldassarre, M; D'Urso, R; Del Roscio, S; Falaschi, P; Frajese, G; Mearelli, S; Rocco, A; Ruggieri, S1
Bushenbark, K; Esterlitz, J; Gauger, L; Hauser, RA; Hubble, J; Koller, W; Lilienfeld, D; Malapira, T; Olanow, CW1
Eadie, MJ1
Ludin, HP1
Janjua, R; Roos, RA; van Kempen, GM1
Danysz, W; Quack, G; Rogoz, Z; Skuza, G1
Kintzer, PP; Peterson, ME1
Eberli, F; Greminger, P; Schmid, PA; Speich, R; Suter, T1
Dichgans, J; Klockgether, T1
Curry, PT; Kitchin, RM; Motimaya, AM; Subramanya, KS1
Lees, AJ1
Calzetti, S; Cassio, A; Negrotti, A1
Ahlskog, JE1
Kishore, A; Snow, BJ1
Dierks, T; Grosse, H; Kuhn, W; Müller, T; Rommelspacher, H1
Montastruc, JL; Rascol, O; Senard, JM1
McCallum, RW; Sarosiek, I; Shifflett, J; Soykan, I; Wooten, GF1
Baudewig, J; Bruns, D; Paulus, W; Tergau, F; Ziemann, U1
Brooks, DJ; Brunt, ER; Korczyn, AD; Poewe, WH; Rascol, O; Stocchi, F1
Abrams, KR1
Ben-Shlomo, Y; Churchyard, A; Head, J; Hurwitz, B; Lees, AJ; Ockelford, J; Overstall, P1
Busenbark, K; Hauser, RA; Hubble, JP; Koller, WC; Malapira, T; Olanow, CW1
Haapaniemi, TH; Kallio, MA; Korpelainen, JT; Myllylä, VV; Sotaniemi, KA; Suominen, K; Tolonen, U1
Sternon, J; Supiot, F; Zegers de Beyl, D1
Bizzarri, G; Calzetti, S; Negrotti, A1
Haapaniemi, TH; Korpelainen, JT; Myllylä, VV; Sotaniemi, KA; Suominen, K; Tolonen, U1
Ben-Shlomo, Y; Head, J; Katzenschlager, R; Lees, AJ1
Okamoto, K; Tanaka, M1
Mitsumoto, Y; Mori, A; Moriizumi, T; Nakai, M; Ohashi, S1
Goetz, CG; Poewe, W; Rascol, O; Sampaio, C1
Chan, PL; Holford, NH; Kieburtz, K; Nutt, JG; Shoulson, I1
Hirohata, M; Ono, K; Yamada, M1
Ben-Shlomo, Y; Evans, A; Head, J; Katzenschlager, R; Lees, AJ; Schrag, A1
El Otmani, H; Fadel, H; Moutaouakil, F; Slassi, I1
Schneemilch, C1
Agúndez, JA; Alonso-Navarro, H; García-Martín, E; Jiménez-Jiménez, FJ1
Ji, F; Jiang, R; Su, Z; Xue, R; Zhou, Y; Zhu, X; Zhuo, C1

Reviews

19 review(s) available for bromocriptine and selegiline

ArticleYear
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016
Toward the discovery and development of effective modulators of α-synuclein amyloid aggregation.
    European journal of medicinal chemistry, 2019, Apr-01, Volume: 167

    Topics: alpha-Synuclein; Amyloidogenic Proteins; Drug Discovery; Humans; Protein Aggregation, Pathological; Structure-Activity Relationship

2019
Recent advances in research on Parkinsonism.
    Acta neurologica Scandinavica. Supplementum, 1978, Volume: 67

    Topics: Acetylcholinesterase; Adult; Apomorphine; Benserazide; Brain; Bromocriptine; Carbidopa; Dopa Decarboxylase; Dopamine; Drug Therapy, Combination; gamma-Aminobutyric Acid; Humans; Levodopa; Norepinephrine; Parkinson Disease; Selegiline; Serotonin; Substance P; Tyrosine 3-Monooxygenase

1978
[Current therapeutic approach in Parkinson disease].
    Revue medicale de Bruxelles, 1992, Volume: 13, Issue:10

    Topics: Antiparkinson Agents; Apomorphine; Bromocriptine; Fetal Tissue Transplantation; Humans; Levodopa; Mesencephalon; Parkinson Disease; Selegiline; Vitamin E

1992
[New anti-parkinsonian drugs].
    No to shinkei = Brain and nerve, 1991, Volume: 43, Issue:8

    Topics: Antiparkinson Agents; Bromocriptine; Humans; Lisuride; Parkinson Disease; Pergolide; Picolinic Acids; Selegiline

1991
New perspectives in the treatment of Parkinson's disease.
    Clinical neuropharmacology, 1986, Volume: 9 Suppl 1

    Topics: Bromocriptine; Dopamine; Drug Therapy, Combination; Humans; Levodopa; Parkinson Disease; Receptors, Dopamine; Selegiline; Sincalide

1986
'On-off' phenomenon: description, incidence and management.
    European neurology, 1987, Volume: 27 Suppl 1

    Topics: Bromocriptine; Dose-Response Relationship, Drug; Humans; Levodopa; Monoamine Oxidase Inhibitors; Movement Disorders; Parkinson Disease; Selegiline

1987
Controversies in the management of Parkinson's disease.
    Movement disorders : official journal of the Movement Disorder Society, 1986, Volume: 1, Issue:3

    Topics: Bromocriptine; Drug Therapy, Combination; Humans; Levodopa; Parkinson Disease; Selegiline

1986
Update on the treatment of Parkinson's disease.
    Connecticut medicine, 1985, Volume: 49, Issue:10

    Topics: Amantadine; Bromocriptine; Carbidopa; Drug Synergism; Humans; Levodopa; Parasympatholytics; Parkinson Disease; Selegiline; Time Factors

1985
Update on antiparkinsonian agents.
    Geriatrics, 1982, Volume: 37, Issue:9

    Topics: Aged; Amantadine; Antiparkinson Agents; Blood-Brain Barrier; Bromocriptine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Gastrointestinal Diseases; Histamine H1 Antagonists; Humans; Levodopa; Parasympatholytics; Parkinson Disease; Receptors, Dopamine; Selegiline; Vascular Resistance

1982
The pharmacology of Parkinson's disease: basic aspects and recent advances.
    Experientia, 1984, Nov-15, Volume: 40, Issue:11

    Topics: Animals; Antiparkinson Agents; Aromatic Amino Acid Decarboxylase Inhibitors; Benserazide; Brain; Bromocriptine; Carbidopa; Corpus Striatum; Dopamine; Ergolines; Humans; Kidney; Kinetics; Levodopa; Lisuride; Liver; Methyldopa; Norepinephrine; Parkinson Disease; Pergolide; Receptors, Dopamine; Selegiline; Serotonin; Stereotyped Behavior; Substantia Nigra; Tyramine

1984
[Stage-adjusted treatment of idiopathic Parkinson syndrome].
    Wiener medizinische Wochenschrift (1946), 1995, Volume: 145, Issue:13

    Topics: Antiparkinson Agents; Bromocriptine; Carboxy-Lyases; Cholinergic Antagonists; Disability Evaluation; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Humans; Levodopa; Neurologic Examination; Parkinson Disease; Selegiline

1995
Medical treatment of pituitary-dependent hyperadrenocorticism in dogs.
    Seminars in veterinary medicine and surgery (small animal), 1994, Volume: 9, Issue:3

    Topics: Animals; Bromocriptine; Cushing Syndrome; Cyproheptadine; Dog Diseases; Dogs; Drug Administration Schedule; Ketoconazole; Mitotane; Selegiline

1994
Treatment of early Parkinson's disease: are complicated strategies justified?
    Mayo Clinic proceedings, 1996, Volume: 71, Issue:7

    Topics: Animals; Antiparkinson Agents; Bromocriptine; Carbidopa; Drug Therapy, Combination; Humans; Levodopa; Parkinson Disease; Pergolide; Selegiline

1996
Drug management of Parkinson's disease.
    Canadian family physician Medecin de famille canadien, 1996, Volume: 42

    Topics: Amantadine; Antiparkinson Agents; Bromocriptine; Humans; Levodopa; Parkinson Disease; Selegiline; Trihexyphenidyl

1996
New directions in the drug treatment of Parkinson's disease.
    Drugs & aging, 1996, Volume: 9, Issue:3

    Topics: Antiparkinson Agents; Apomorphine; Bromocriptine; Dopamine Agonists; Humans; Levodopa; Neuroprotective Agents; Parkinson Disease; Selegiline

1996
Evidence-based medical review update: pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004.
    Movement disorders : official journal of the Movement Disorder Society, 2005, Volume: 20, Issue:5

    Topics: Amantadine; Antiparkinson Agents; Apomorphine; Benzophenones; Benzothiazoles; Bromocriptine; Cabergoline; Catechol O-Methyltransferase Inhibitors; Deep Brain Stimulation; Dihydroergocryptine; Ergolines; Fetal Tissue Transplantation; Globus Pallidus; Humans; Indans; Indoles; Levodopa; Lisuride; Mesencephalon; Monoamine Oxidase Inhibitors; Neurosurgical Procedures; Nitrophenols; Parkinson Disease; Pergolide; Piribedil; Pramipexole; Selegiline; Thiazoles; Tolcapone

2005
Anti-Parkinson's disease drugs and pharmacogenetic considerations.
    Expert opinion on drug metabolism & toxicology, 2013, Volume: 9, Issue:7

    Topics: Aryl Hydrocarbon Hydroxylases; Benzothiazoles; Benztropine; Bromocriptine; Cabergoline; Catechols; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP1A2 Inhibitors; Cytochrome P-450 CYP2B6; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP3A; Ergolines; Genetic Markers; Humans; Indans; Indoles; Levodopa; Lisuride; Nitriles; Parkinson Disease; Pergolide; Pharmacogenetics; Pramipexole; Receptors, Dopamine D2; Receptors, Dopamine D3; Reproducibility of Results; Selegiline

2013
Comparison for Efficacy and Tolerability among Ten Drugs for Treatment of Parkinson's Disease: A Network Meta-Analysis.
    Scientific reports, 2017, 04-04, Volume: 8

    Topics: Bromocriptine; Cluster Analysis; Dopamine Agonists; Drug Therapy, Combination; Humans; Indoles; Levodopa; Network Meta-Analysis; Parkinson Disease; Picolinic Acids; Pramipexole; Selegiline; Tetrahydronaphthalenes; Thiophenes

2017

Trials

16 trial(s) available for bromocriptine and selegiline

ArticleYear
The effect of dietary protein on the efficacy of L-dopa: a double-blind study.
    Neurology, 1989, Volume: 39, Issue:4

    Topics: Antiparkinson Agents; Bromocriptine; Carbidopa; Clinical Trials as Topic; Dietary Proteins; Double-Blind Method; Drug Combinations; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Random Allocation; Selegiline

1989
The effect of deprenyl and levodopa on the progression of Parkinson's disease.
    Annals of neurology, 1995, Volume: 38, Issue:5

    Topics: Aged; Analysis of Variance; Antiparkinson Agents; Bromocriptine; Carbidopa; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Drug Therapy, Combination; Female; Humans; Least-Squares Analysis; Levodopa; Male; Parkinson Disease; Prospective Studies; Selegiline; Statistics, Nonparametric; Treatment Outcome

1995
Visual control of arm movement in Parkinson's disease.
    Movement disorders : official journal of the Movement Disorder Society, 1994, Volume: 9, Issue:1

    Topics: Adult; Aged; Attention; Benserazide; Bromocriptine; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Motor Skills; Orientation; Parkinson Disease; Psychomotor Performance; Reaction Time; Selegiline

1994
Comparisons of therapeutic effects of levodopa, levodopa and selegiline, and bromocriptine in patients with early, mild Parkinson's disease: three year interim report. Parkinson's Disease Research Group in the United Kingdom.
    BMJ (Clinical research ed.), 1993, Aug-21, Volume: 307, Issue:6902

    Topics: Adult; Aged; Aged, 80 and over; Bromocriptine; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Prospective Studies; Selegiline; Treatment Outcome

1993
Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson's disease. Parkinson's Disease Research Group of the United Kingdom.
    BMJ (Clinical research ed.), 1995, Dec-16, Volume: 311, Issue:7020

    Topics: Antiparkinson Agents; Benserazide; Bromocriptine; Cause of Death; Disability Evaluation; Drug Administration Schedule; Drug Therapy, Combination; Follow-Up Studies; Humans; Levodopa; Monoamine Oxidase Inhibitors; Parkinson Disease; Proportional Hazards Models; Prospective Studies; Selegiline; Time Factors; Treatment Failure

1995
L-deprenyl as an adjunct to low-dose bromocriptine in early Parkinson's disease: a short-term, double-blind, and prospective follow-up study.
    Clinical neuropharmacology, 1995, Volume: 18, Issue:3

    Topics: Aged; Antiparkinson Agents; Bromocriptine; Chemotherapy, Adjuvant; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Male; Parkinson Disease; Placebos; Prospective Studies; Selegiline

1995
Effect of chronic oral domperidone therapy on gastrointestinal symptoms and gastric emptying in patients with Parkinson's disease.
    Movement disorders : official journal of the Movement Disorder Society, 1997, Volume: 12, Issue:6

    Topics: Aged; Antiparkinson Agents; Bromocriptine; Carbidopa; Domperidone; Dopamine Antagonists; Drug Therapy, Combination; Female; Follow-Up Studies; Gastric Emptying; Gastrointestinal Diseases; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Selegiline; Severity of Illness Index

1997
Changes in human motor cortex excitability induced by dopaminergic and anti-dopaminergic drugs.
    Electroencephalography and clinical neurophysiology, 1997, Volume: 105, Issue:6

    Topics: Administration, Oral; Adult; Analysis of Variance; Bromocriptine; Dopamine Agonists; Dopamine Antagonists; Electromyography; Evoked Potentials, Motor; Female; Haloperidol; Humans; Levodopa; Magnetics; Male; Motor Cortex; Physical Stimulation; Reference Values; Selegiline; Sulpiride

1997
Ropinirole versus bromocriptine in the treatment of early Parkinson's disease: a 6-month interim report of a 3-year study. 053 Study Group.
    Movement disorders : official journal of the Movement Disorder Society, 1998, Volume: 13, Issue:1

    Topics: Adult; Aged; Antiparkinson Agents; Bromocriptine; Confidence Intervals; Disease Progression; Dopamine Agonists; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Indoles; Longitudinal Studies; Male; Middle Aged; Odds Ratio; Parkinson Disease; Regression Analysis; Selegiline; Severity of Illness Index; Treatment Outcome

1998
Investigation by Parkinson's Disease Research Group of United Kingdom into excess mortality seen with combined levodopa and selegiline treatment in patients with early, mild Parkinson's disease: further results of randomised trial and confidential inquiry
    BMJ (Clinical research ed.), 1998, Apr-18, Volume: 316, Issue:7139

    Topics: Antiparkinson Agents; Bromocriptine; Cause of Death; Disabled Persons; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Levodopa; Male; Parkinson Disease; Proportional Hazards Models; Selegiline; Survival Rate; Treatment Failure

1998
Time course of loss of clinical benefit following withdrawal of levodopa/carbidopa and bromocriptine in early Parkinson' s disease.
    Movement disorders : official journal of the Movement Disorder Society, 2000, Volume: 15, Issue:3

    Topics: Aged; Antiparkinson Agents; Bromocriptine; Carbidopa; Disability Evaluation; Disease Progression; Double-Blind Method; Female; Humans; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Prospective Studies; Selegiline; Substance Withdrawal Syndrome

2000
Levodopa, bromocriptine and selegiline modify cardiovascular responses in Parkinson's disease.
    Journal of neurology, 2000, Volume: 247, Issue:11

    Topics: Aged; Blood Pressure; Bromocriptine; Cardiovascular System; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Selegiline

2000
Long-term persistence of symptomatic effect of selegiline in Parkinson's disease. A two-months placebo-controlled withdrawal study.
    Journal of neural transmission (Vienna, Austria : 1996), 2001, Volume: 108, Issue:2

    Topics: Aged; Antiparkinson Agents; Bromocriptine; Female; Humans; Male; Middle Aged; Motor Activity; Parkinson Disease; Selegiline; Severity of Illness Index; Single-Blind Method; Substance Withdrawal Syndrome

2001
Suppressed sympathetic skin response in Parkinson disease.
    Clinical autonomic research : official journal of the Clinical Autonomic Research Society, 2000, Volume: 10, Issue:6

    Topics: Acoustic Stimulation; Aged; Antiparkinson Agents; Bromocriptine; Carbidopa; Electric Stimulation; Evoked Potentials; Evoked Potentials, Auditory; Female; Foot; Hand; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Reaction Time; Reference Values; Selegiline; Skin; Sympathetic Nervous System

2000
Ten-year follow-up of three different initial treatments in de-novo PD: a randomized trial.
    Neurology, 2001, Nov-13, Volume: 57, Issue:9

    Topics: Antiparkinson Agents; Aromatic Amino Acid Decarboxylase Inhibitors; Bromocriptine; Disability Evaluation; Dyskinesia, Drug-Induced; Female; Follow-Up Studies; Humans; Incidence; Levodopa; Male; Parkinson Disease; Selegiline; Treatment Outcome

2001
Fourteen-year final report of the randomized PDRG-UK trial comparing three initial treatments in PD.
    Neurology, 2008, Aug-12, Volume: 71, Issue:7

    Topics: Antiparkinson Agents; Bromocriptine; Disability Evaluation; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Motor Skills; Parkinson Disease; Quality of Life; Selegiline

2008

Other Studies

31 other study(ies) available for bromocriptine and selegiline

ArticleYear
Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs.
    The Journal of pharmacology and experimental therapeutics, 2002, Volume: 303, Issue:3

    Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blood-Brain Barrier; Cell Line; Cell Membrane Permeability; Central Nervous System Agents; Dogs; Drug Delivery Systems; Permeability; Pharmaceutical Preparations

2002
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
    Current drug discovery technologies, 2004, Volume: 1, Issue:4

    Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration

2004
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
    Journal of medicinal chemistry, 2008, Nov-13, Volume: 51, Issue:21

    Topics: Computational Biology; Drug Design; Humans; Isoenzymes; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Quantitative Structure-Activity Relationship

2008
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
    Chemical research in toxicology, 2010, Volume: 23, Issue:1

    Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship

2010
Oscillations in performance in levodopa-treated parkinsonians: treatment with bromocriptine and L-deprenyl.
    Clinical and experimental neurology, 1979, Volume: 16

    Topics: Bromocriptine; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Movement Disorders; Parkinson Disease; Phenethylamines; Selegiline

1979
Overview of present day treatment of Parkinson's disease.
    Journal of neural transmission, 1978, Volume: 43, Issue:3-4

    Topics: Adult; Aged; Bromocriptine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Phenethylamines; Receptors, Dopamine; Selegiline

1978
Dopamine agonists used as monotherapy in de novo PD patients: comparisons with selegiline.
    Neurology, 1992, Volume: 42, Issue:4 Suppl 4

    Topics: Bromocriptine; Clinical Trials as Topic; Dopamine Agents; Humans; Levodopa; Middle Aged; Parkinson Disease; Selegiline

1992
Treating the progressive stages of Parkinson's disease.
    Postgraduate medicine, 1991, Volume: 90, Issue:1

    Topics: Amantadine; Antiparkinson Agents; Bromocriptine; Carbidopa; Drug Combinations; Electroconvulsive Therapy; Humans; Levodopa; Parasympatholytics; Parkinson Disease; Pergolide; Selegiline

1991
Current and future approaches to therapy.
    Advances in neurology, 1987, Volume: 45

    Topics: Antiparkinson Agents; Benserazide; Bromocriptine; Carbidopa; Drug Therapy, Combination; Humans; Levodopa; Lisuride; Parkinson Disease; Selegiline

1987
Parkinson's disease in the elderly: current management strategies.
    Geriatrics, 1987, Volume: 42, Issue:7

    Topics: Aged; Amantadine; Antiparkinson Agents; Bromocriptine; Drug Administration Schedule; Drug Therapy, Combination; Humans; Levodopa; Parasympatholytics; Parkinson Disease; Selegiline

1987
Milestones in the development of modern Parkinson therapy.
    Journal of neural transmission. Supplementum, 1987, Volume: 25

    Topics: 2,3-Diketogulonic Acid; Alloxan; Behavior; Bromocriptine; Drug Combinations; Drug Therapy, Combination; Ferric Compounds; Humans; Levodopa; Neurology; Parkinson Disease; Selegiline; Tryptophan

1987
Drugs for parkinsonism.
    The Medical letter on drugs and therapeutics, 1988, Dec-16, Volume: 30, Issue:781

    Topics: Amantadine; Bromocriptine; Carbidopa; Drug Combinations; Humans; Levodopa; Parasympatholytics; Parkinson Disease; Selegiline

1988
Neuroendocrine aspects in monitoring of dopaminergic drugs in man.
    Methods and findings in experimental and clinical pharmacology, 1985, Volume: 7, Issue:8

    Topics: Apomorphine; Bromocriptine; Growth Hormone; Homovanillic Acid; Humans; Levodopa; Male; Metoclopramide; Monitoring, Physiologic; Neurosecretory Systems; Prolactin; Receptors, Dopamine; Schizophrenia; Selegiline; Time Factors

1985
Combination treatment with selective monoamine oxidase inhibitors and dopaminergic agonists in Parkinson's disease: biochemical and clinical observations.
    Advances in neurology, 1983, Volume: 37

    Topics: Bromocriptine; Dopamine; Drug Therapy, Combination; Humans; Lisuride; Monoamine Oxidase Inhibitors; Parkinson Disease; Selegiline; Tranylcypromine

1983
Adjuvant drugs in the treatment of on-off phenomena in Parkinson's disease.
    Advances in neurology, 1984, Volume: 40

    Topics: Benzamides; Bromocriptine; Carboxy-Lyases; Drug Therapy, Combination; Humans; Levodopa; Parkinson Disease; Phenethylamines; Selegiline; Tiapamil Hydrochloride

1984
Human growth hormone and dopaminergic drugs, with special reference to deprenyl (selegiline): a summary of studies on volunteers.
    Acta neurologica Scandinavica. Supplementum, 1983, Volume: 95

    Topics: Apomorphine; Bromocriptine; Dopamine; gamma-Aminobutyric Acid; Growth Hormone; Humans; Levodopa; Phenethylamines; Receptors, Dopamine; Selegiline; Synapses

1983
Presynaptic neuron and postsynaptic dopamine receptor function in long term treatment of Parkinson's disease: a neuroendocrine study.
    Progress in clinical and biological research, 1980, Volume: 39

    Topics: Aged; Apomorphine; Benserazide; Bromocriptine; Carbidopa; Female; Humans; Levodopa; Male; Middle Aged; Nomifensine; Parkinson Disease; Prolactin; Receptors, Dopamine; Selegiline; Tremor

1980
Treatment of Parkinson's disease.
    Australian family physician, 1995, Volume: 24, Issue:9

    Topics: Antiparkinson Agents; Bromocriptine; Humans; Levodopa; Monoamine Oxidase Inhibitors; Parkinson Disease; Pergolide; Prognosis; Selegiline

1995
Effect of disease and drug treatment on blood serotonin and monoamine oxidase B activity in Parkinson's disease.
    Clinical neurology and neurosurgery, 1995, Volume: 97, Issue:2

    Topics: Adult; Aged; Amantadine; Blood Platelets; Bromocriptine; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Monoamine Oxidase; Parkinson Disease; Selegiline; Serotonin; Treatment Outcome

1995
Memantine, amantadine, and L-deprenyl potentiate the action of L-dopa in monoamine-depleted rats.
    Journal of neural transmission. General section, 1994, Volume: 98, Issue:1

    Topics: Amantadine; Animals; Bromocriptine; Dopamine; Drug Synergism; Levodopa; Male; Memantine; Motor Activity; N-Methylaspartate; Parkinson Disease; Rats; Rats, Wistar; Selegiline

1994
[Bromocriptine-induced pleuropneumopathy].
    Deutsche medizinische Wochenschrift (1946), 1994, Nov-11, Volume: 119, Issue:45

    Topics: Benserazide; Biperiden; Bromocriptine; Humans; Levodopa; Lung Diseases; Male; Middle Aged; Parkinson Disease; Pleural Effusion; Pulmonary Atelectasis; Pulmonary Fibrosis; Radiography; Selegiline; Time Factors

1994
Assessment of genotoxicity of two anti-parkinsonian drugs (selegiline hydrochloride and bromocriptine mesylate) in vivo in mouse bone marrow cells.
    Toxicology letters, 1993, Volume: 66, Issue:3

    Topics: Analysis of Variance; Animals; Bone Marrow; Bone Marrow Cells; Bromocriptine; Cell Survival; Erythrocytes; Female; Injections, Intraperitoneal; Male; Mice; Micronucleus Tests; Mutagens; Selegiline

1993
Plasma levels of the beta-carbolines harman and norharman in Parkinson's disease.
    Acta neurologica Scandinavica, 1995, Volume: 92, Issue:6

    Topics: Aged; Antiparkinson Agents; Bromocriptine; Carbolines; Female; Humans; Levodopa; Male; Middle Aged; Mitochondria; Parkinson Disease; Selegiline

1995
Monitoring randomised controlled trials. Parkinson's disease trial illustrates the dangers of stopping early.
    BMJ (Clinical research ed.), 1998, Apr-18, Volume: 316, Issue:7139

    Topics: Antiparkinson Agents; Bromocriptine; Decision Making; Humans; Levodopa; Parkinson Disease; Randomized Controlled Trials as Topic; Selegiline

1998
[Dopaminergic agonists in the treatment of Parkinson's disease].
    Revue medicale de Bruxelles, 2000, Volume: 21, Issue:6

    Topics: Aged; Antiparkinson Agents; Apomorphine; Benzothiazoles; Biological Availability; Bromocriptine; Catechols; Dopamine Agonists; Drug Combinations; Drug Hypersensitivity; Humans; Hypotension, Orthostatic; Indoles; Levodopa; Metabolic Clearance Rate; Nitriles; Parkinson Disease; Pergolide; Pramipexole; Selegiline; Thiazoles

2000
[Therapy for patients with early-stage Parkinson's disease].
    Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine, 2003, Aug-10, Volume: 92, Issue:8

    Topics: Amantadine; Animals; Antiparkinson Agents; Bromocriptine; Dopamine Agonists; Drug Therapy, Combination; Humans; Levodopa; Monoamine Oxidase Inhibitors; Parkinson Disease; Practice Guidelines as Topic; Selegiline; Trihexyphenidyl

2003
Neural mechanisms underlying motor dysfunction as detected by the tail suspension test in MPTP-treated C57BL/6 mice.
    Neuroscience research, 2005, Volume: 51, Issue:3

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Analysis of Variance; Animals; Behavior, Animal; Blotting, Western; Brain Chemistry; Bromocriptine; Corpus Striatum; Dopamine; Dopamine Agents; Dopamine Agonists; Dopamine Plasma Membrane Transport Proteins; Dose-Response Relationship, Drug; Drug Interactions; Hindlimb Suspension; Immobility Response, Tonic; Immunohistochemistry; Levodopa; Male; Membrane Glycoproteins; Membrane Transport Proteins; Mice; Mice, Inbred C57BL; Monoamine Oxidase Inhibitors; Motor Activity; Nerve Tissue Proteins; Selegiline; Time Factors; Tyrosine 3-Monooxygenase

2005
Disease progression and pharmacodynamics in Parkinson disease - evidence for functional protection with levodopa and other treatments.
    Journal of pharmacokinetics and pharmacodynamics, 2006, Volume: 33, Issue:3

    Topics: Algorithms; Antiparkinson Agents; Bayes Theorem; Bromocriptine; Disease Progression; Dopamine Agonists; Drug Therapy, Combination; Humans; Levodopa; Models, Biological; Parkinson Disease; Pergolide; Randomized Controlled Trials as Topic; Selegiline; Treatment Outcome

2006
Anti-fibrillogenic and fibril-destabilizing activities of anti-Parkinsonian agents for alpha-synuclein fibrils in vitro.
    Journal of neuroscience research, 2007, May-15, Volume: 85, Issue:7

    Topics: alpha-Synuclein; Antiparkinson Agents; Bromocriptine; Dopamine; Dose-Response Relationship, Drug; In Vitro Techniques; Molecular Structure; Neurofibrillary Tangles; Pergolide; Polymers; Selegiline; Trihexyphenidyl

2007
[Severe apathy following head injury: improvement with Selegiline treatment].
    Neuro-Chirurgie, 2009, Volume: 55, Issue:6

    Topics: Adolescent; Adult; Behavior; Bromocriptine; Craniocerebral Trauma; Dopamine Agonists; Emotions; Glasgow Coma Scale; Humans; Magnetic Resonance Imaging; Male; Mental Disorders; Monoamine Oxidase Inhibitors; Motivation; Prefrontal Cortex; Radiography; Selegiline

2009
[General anaesthesia for neurological diseases].
    Anasthesiologie, Intensivmedizin, Notfallmedizin, Schmerztherapie : AINS, 2010, Volume: 45, Issue:5

    Topics: Anesthesia, General; Anesthetics, Inhalation; Anesthetics, Intravenous; Autonomic Nervous System; Brain; Bromocriptine; Dopamine Agonists; Humans; Intubation; Levodopa; Monoamine Oxidase Inhibitors; Muscle Relaxants, Central; Nervous System Diseases; Neurodegenerative Diseases; Neurosurgery; Parkinson Disease; Piperidines; Premedication; Preoperative Care; Propofol; Remifentanil; Selegiline; Stereotaxic Techniques; Syndrome

2010